Navigation Links
Abbott's Investigational MitraClip(R) System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves
Date:5/25/2010

Additionally, Abbott presented results on a subset of patients within the EVEREST II trial who had progressed to two years post procedure, which showed that the positive clinical results achieved at one year with the MitraClip system are sustained at two years in patients with significant MR. The preliminary two-year results evaluated 86 of the 217 patients who had successful MR reduction after treatment with a MitraClip device or open heart surgery, and showed there was no difference in the need for subsequent mitral valve surgery through two years between these two groups.

"The patient subgroup analysis shows that the catheter-based clip device delivers consistent results regardless of FMR or DMR etiology. These results are important because they are consistent with the results achieved in the EVEREST High Risk Registry Study, indicating the device may be an option for treatment for a range of patients with MR," said Ted Feldman, M.D., FSCAI, director, Cardiac Catheterization Laboratory, and The Mr. and Mrs. Charles R. Walgreen Chair in Interventional Cardiology, NorthShore University HealthSystem, Evanston, IL; and co-principal investigator of the EVEREST II trial. "In addition, the data on the durability of the clip device compared to surgery through two years adds to my confidence that a treatment strategy with the clip may be a viable choice for certain patients who are looking for other options to treat their leaky heart valve."

The MitraClip system includes a catheter-based device, which is delivered to the heart through a blood vessel in the leg (femoral vein). The MitraClip device is designed to reduce significant MR by clipping together the leaflets of the mitral valve (one of the four valves of the heart). Mitral regurgitation affects more than 8 million people in the United States and '/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... LAGUNA HILLS, Calif. , July 30, 2015 ... developing nanoparticle drug delivery platforms, has received Orphan ... (FDA) for a second drug product that uses ... is a formulation of dactinomycin for the treatment ... bone cancer. The FDA granted NanoSmart,s Orphan Drug ...
(Date:7/30/2015)... 30, 2015 Flexpoint Ford, a private equity ... today announced that it has entered into a partnership ... to form Kastle Therapeutics, LLC (Kastle).  The new ... focus on acquiring, developing and commercializing pharmaceuticals targeted toward ... include select therapies already approved for marketing, as well ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... 2012  Genalyte, Inc., a life sciences company developing ... completion of an $11.8 million Series B financing.  ... and private investors from Genalyte,s Series A round ... to use the new funds primarily for commercialization ...
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and store adult stem cells, said today that its ... first company in China to receive accreditation from the ... is an international, not-for-profit association representing nearly 2,000 institutions ...
Cached Medicine Technology:Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 2Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 3ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China 2ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China 3
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... Using ... eradicate suicide and teach people more effective ways to prevent and manage major depression. ... to react fast enough, so people fall through the cracks and die needlessly everyday,” ...
(Date:7/30/2015)... Mequon, Wisconsin (PRWEB) , ... July 30, 2015 , ... ... rejuvenation. Kybella is a nonsurgical treatment designed specifically for the elimination ... is one of the first locations in the state of Wisconsin to offer this ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Tisch ... Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn School of ... center. TCI joins an elite group of 69 cancer institutions nationwide that have ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos seeks ... in his new self-help book, “ Consciously Healing our Webs of Health, Wellbeing, Success, ... message: “If we take responsibility for ourselves, we can create better realities.” His book ...
(Date:7/30/2015)... Washington, DC (PRWEB) , ... July 30, 2015 ... ... in a fight with its Medicare administrative contractor (MAC) over submitted claims for ... rejected. Calling it a challenge to program integrity, Becky Dennis, a nurse auditor ...
Breaking Medicine News(10 mins):Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3
... Help Kids Worldwide, NEW YORK, Feb. 4 ... are being asked to submit creative,drawings for the 2008 ... One winner will be chosen from thousands of,entries and ... UNICEF,holiday greeting card, sold exclusively at Pier 1 Imports ...
... YORK, February 4, 2008 The Juvenile Diabetes ... of type 1 diabetes research, announced today that ... company based in Winston-Salem, N.C. that focuses on ... Through its Industry Discovery and Development Partnership Program, ...
... Feb. 4 Renowned esthetician, Karen,Dunlap, has developed ... recognized as the number-one most nutritious and powerful ... the dots between science and,nature, Dunlap discovered that ... -- magnifies its benefits. Her new signature facial, ...
... and 4 percent of former illicit drug users ... year following an organ transplant. These results are ... a journal by John Wiley & Sons. The ... ( http://www.interscience.wiley.com/journal/livertransplantation ). , Substance abuse can lead ...
... 2008 Contrary to previous research, older adults who use ... reduced risk of developing dementia or Alzheimers disease. This is ... the American Geriatrics Society that tracked patients using vitamin E ... than 5 years. The study also finds that the combined ...
... connecting patients and caregivers offers tips to families, ... ... helpful, CHICAGO, Feb. 4 What do you say, what ... or suffering from a serious,disease? To kick-off National Patient Recognition Week, ...
Cached Medicine News:Health News:Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest 2Health News:Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest 3Health News:JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells 2Health News:Breakthrough 'Acai Berry Anti-Aging Facial' Applies Benefits of Nature's Super-Food to the Skin 2Health News:Former substance abusers rarely relapse after organ transplantation 2Health News:Vitamin E or C does not reduce risk of dementia or Alzheimer's 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: